Insider Selling: Stryker (NYSE:SYK) Director Sells 310,000 Shares of Stock

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Stryker Trading Up 0.4%

Shares of SYK stock traded up $1.28 during mid-day trading on Thursday, reaching $307.22. 2,438,898 shares of the stock traded hands, compared to its average volume of 2,259,196. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $117.78 billion, a price-to-earnings ratio of 35.56, a price-to-earnings-growth ratio of 1.97 and a beta of 0.80. The stock’s fifty day simple moving average is $323.45 and its two-hundred day simple moving average is $348.79.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter last year, the business earned $2.84 earnings per share. Stryker’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on SYK shares. Truist Financial restated a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Barclays cut their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. UBS Group cut their target price on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. Finally, William Blair reaffirmed an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.48.

Institutional Trading of Stryker

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. VanderPol Investments L.L.C. raised its stake in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC raised its stake in shares of Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC increased its stake in Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares during the last quarter. Lantz Financial LLC increased its stake in Stryker by 5.0% in the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock worth $225,000 after acquiring an additional 29 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC increased its stake in Stryker by 0.4% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after acquiring an additional 29 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.